Growth Metrics

Catalyst Pharmaceuticals (CPRX) Non-Current Assets (2010 - 2026)

Catalyst Pharmaceuticals posted quarterly Non-Current Assets of $207.2 million for Q1 2026, down 7.14% year-on-year from $223.2 million in Q1 2025, and down 1.3% on a QoQ basis from $209.9 million in Q4 2025.

Catalyst Pharmaceuticals (CPRX) has 17 years of Non-Current Assets data on file, last reported at $207.2 million in Q1 2026.

  • For the quarter ending Q1 2026, Non-Current Assets fell 7.14% year-over-year to $207.2 million; the trailing twelve-month figure through Mar 2026 stood at $829.5 million (down 9.43% YoY), and the FY2025 full-year result was $209.9 million, down 7.84% from the prior year.
  • Non-Current Assets for Q1 2026 stood at $207.2 million, down from $209.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $250.8 million in Q4 2023 and bottomed at $24.8 million in Q2 2022.
  • The 5-year median for Non-Current Assets is $209.9 million (2025), against an average of $178.4 million.
  • The widest annual swing landed in 2022, when Non-Current Assets fell 27.75%; it then jumped 719.88% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $54.8 million in 2022, then surged by 357.44% to $250.8 million in 2023, then declined by 9.16% to $227.8 million in 2024, then retreated by 7.84% to $209.9 million in 2025, then retreated by 1.3% to $207.2 million in 2026.
  • The last three Non-Current Assets figures came in at $207.2 million (Q1 2026), $209.9 million (Q4 2025), and $199.1 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 4.56 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 62,953.78
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 486.60 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 5.83 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 30.30 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 14.75 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 22.66 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 910.24 Mn
10 Catalyst Pharmaceuticals 3.82 Bn 3.07 Bn 134.92 Mn 207.22 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 207.22 Mn
Dec 31, 2025 209.95 Mn
Sep 30, 2025 199.15 Mn
Jun 30, 2025 213.18 Mn
Mar 31, 2025 223.15 Mn
Dec 31, 2024 227.80 Mn
Sep 30, 2024 233.01 Mn
Jun 30, 2024 231.93 Mn
Mar 31, 2024 242.07 Mn
Dec 31, 2023 250.79 Mn
Sep 30, 2023 221.19 Mn
Jun 30, 2023 202.93 Mn
Mar 31, 2023 208.32 Mn
Dec 31, 2022 54.82 Mn
Sep 30, 2022 56.80 Mn
Jun 30, 2022 24.75 Mn
Mar 31, 2022 25.78 Mn
Dec 31, 2021 27.68 Mn
Sep 30, 2021 30.45 Mn
Jun 30, 2021 32.83 Mn
Mar 31, 2021 35.68 Mn
Dec 31, 2020 33.11 Mn
Sep 30, 2020 31.52 Mn
Jun 30, 2020 248,113.00
Mar 31, 2020 936,098.00
Dec 31, 2019 1.01 Mn
Sep 30, 2019 6.11 Mn
Jun 30, 2019 6.18 Mn
Mar 31, 2019 6.21 Mn
Dec 31, 2018 5.26 Mn
Sep 30, 2018 5.23 Mn
Jun 30, 2018 5.20 Mn
Mar 31, 2018 192,258.00
Dec 31, 2017 200,273.00
Sep 30, 2017 214,338.00
Jun 30, 2017 227,177.00
Mar 31, 2017 240,134.00
Dec 31, 2016 253,092.00
Sep 30, 2016 257,926.00
Jun 30, 2016 267,406.00
Mar 31, 2016 187,239.00
Dec 31, 2015 200,437.00
Sep 30, 2015 206,523.00
Jun 30, 2015 72,182.00
Mar 31, 2015 80,027.00
Dec 31, 2014 80,265.00
Sep 30, 2014 80,168.00
Jun 30, 2014 74,284.00
Mar 31, 2014 61,537.00
Dec 31, 2013 49,516.00
Sep 30, 2013 55,222.00
Jun 30, 2013 60,929.00
Dec 31, 2012 62,567.00
Mar 31, 2012 23,254.00
Dec 31, 2011 21,074.00
Sep 30, 2011 28,792.00
Jun 30, 2011 36,244.00
Dec 31, 2010 56,084.00